Skip to main content

Human Fibroblast-Like Synoviocytes: HFLS, adult (C15-1303-327)

Catalog No.
C15-1303-327
Manufacturer No.
408-05A
Manufacturer Name
Sigma-Aldrich
Quantity
1
Unit of Measure
EA
Price: $1,697.80
List Price: $1,886.45

Lot specific orders are not able to be placed through the web. Contact your local sales rep for more details.

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added

General description

Lot specific orders are not able to be placed through the web. Contact your local sales rep for more details.

Normal HFLS provide an excellent cellular model for studying the normal and pathological physiology of synoviocytes and development of joint diseases.

Normal HFLS have been used in numerous research studies to:

  • Study changes in gene expression in synoviocytes stimulated with TNFα (Suggiyama, 2002)
  • Demonstrate that TNF-like weak inducer of apoptosis (TWEAK) contributes to joint inflammation by inducing chemokines such as MIP-1β (CCL-4), lymphotactin (XCL-1), IFN-γ-inducible protein 10 (IP-10) (CXCL-10), MCP-1 (CCL-2), and RANTES (CCL-5), as well as the matrix metalloprotease-9, suggesting TWEAK as a new therapeutic target (Perper, 2006)
  • Demonstrate the role of miR-124a in arthritis pathogenesis (Nakamachi, 2009)
  • Show that C/EBPβ regulates expression of metalloproteinases and ADAMTS family members in synoviocytes stimulated with IL-1β (Tsushima, 2012); and that HMW-HA suppressed ADAMTS4 mRNA and protein expression via CD44, p38 MAPK and JNK pathways (Kataoka, 2013)
  • Evaluate the anti-inflammatory and antirheumatic activity of various compounds, such as NF-κB inhibitors (Wen, 2006), AGIX-4207 (Kunsch, 2005), HA–methotrexate conjugates (Homma, 2009) and bucillamine (Oki, 2009)
  • Show that reactive arthritis triggered by chlamydial infection is mediated by TLR2 induced IL-6 production in synoviocytes (Konomi, 2009); and investigate the mechanisms of arthritis-like syndrome in patients infected with chikungunya (CHIK) virus (Xu, 2013)
  • Suggest that only leukocyte-poor, RBC-free platelet-rich plasma should be used in clinical orthopaedics because leukocytes and RBCs cause synoviocyte death and proinflammatory mediator production (Brown, 2014)
  • Identify that cartilage link protein and MAGP2 can be used as specific markers to distinguish chondrocytes and synovial cells (Rapko, 2007, 2010)
  • Create, along with human dermal fibroblasts, induced pluripotent stem cells (iPSC) by using the now classic “Yamanaka cocktail”, the discovery for which Dr. Shinya Yamanaka was awarded the Nobel Prize in 2012 (Takahashi, 2007)

Additionally, in parallel with HFLS isolated from joints of patients with rheumatoid arthritis, normal HFLS were used to:
  • Identify causing agents (such as uric acid crystals or platelet microparticles) and study the immunopathological mechanisms and signal transduction pathways leading to joint inflammation in rheumatoid arthritis (Chen, 2011a; Hsu, 2012; Mathieu, 2008; Tsuji, 2012), and to demonstrate the role of estrogen signaling in increasing inflammation (Galal, 2008)
  • Investigate anti-inflammatory properties of herbal compound Sinomenine suggested for rheumatoid arthritis treatment (Chen, 2011b)
  • Study the effects of extracellular matrix composition on cell attachment and migration relevant to T-cell function in inflamed tissues (Evanko, 2012)

Finally, all three types of HFLS (normal, RA and OA) were used to investigate the role of human endogenous retroviruses (HERVs) in development of rheumatoid arthritis, and suggest that activated expression of different forms of HERV contribute to development of rheumatoid arthritis symptoms by different mechanisms (Freimanis, 2010).

Cell Line Origin

Bone

Application

synoviocyte physiology, joint homeostasis, production of collagen, glycoproteins, lubrican, vimentin and hyaluronic acid, gene expression, signal transduction pathways, enzyme production, evaluation of anti-inflammatory agents, effects of extracellular matrix, cell attachment, migration, integrin study, proinflammatory mediator production

Components

Basal Medium containing 10% FBS & 10% DMSO

Preparation Note

  • 2nd passage, >500,000 cells in Basal Medium containing 10% FBS & 10% DMSO
  • Can be cultured at least 5 doublings

Subculture Routine

Please refer to the HFLS Culture Protocol.

biological source: human synovial tissues (normal). Quality Level: 100. packaging: pkg of 500,000 . cells. manufacturer/tradename: Cell Applications, Inc. growth mode: Adherent. karyotype: 2n : 46. morphology: Fibroblast-like. technique(s): cell culture | mammalian: suitable. relevant disease(s): arthritis. shipped in: dry ice. storage temp.: −. 196°C. Storage Class Code: 11 - Combustible Solids. WGK: WGK 3. Flash Point(F): Not applicable. Flash Point(C): Not applicable.
UPC:
12352202
Condition:
New
Weight:
1.00 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
408-05A


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.